Trade Chugai Pharmaceutical Co., Ltd. - 4519 CFD
Add to favourite- Summary
- Historical Data
| Spread | 18.2 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.012355% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.009867% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | JPY | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | Japan | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7319.9 |
| Open | 7578.4 |
| 1-Year Change | 29.73% |
| Day's Range | 7494.5 - 7691.3 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 7673.4 | 188.9 | 2.52% | 7484.5 | 7694.3 | 7483.5 |
| Feb 20, 2025 | 7319.9 | 28.1 | 0.39% | 7291.8 | 7327.0 | 7132.9 |
| Feb 19, 2025 | 7390.7 | 16.6 | 0.23% | 7374.1 | 7400.7 | 7292.7 |
| Feb 18, 2025 | 7392.7 | 49.0 | 0.67% | 7343.7 | 7413.3 | 7203.8 |
| Feb 17, 2025 | 7355.7 | 79.9 | 1.10% | 7275.8 | 7404.6 | 7253.8 |
| Feb 14, 2025 | 7225.7 | 30.9 | 0.43% | 7194.8 | 7254.8 | 7183.0 |
| Feb 13, 2025 | 7255.8 | 206.2 | 2.92% | 7049.6 | 7273.4 | 7049.6 |
| Feb 12, 2025 | 6989.0 | -48.8 | -0.69% | 7037.8 | 7056.0 | 6930.2 |
| Feb 10, 2025 | 6951.4 | 57.1 | 0.83% | 6894.3 | 6985.2 | 6844.2 |
| Feb 7, 2025 | 6915.2 | 98.8 | 1.45% | 6816.4 | 6931.6 | 6755.3 |
| Feb 6, 2025 | 6764.2 | 56.7 | 0.85% | 6707.5 | 6926.3 | 6694.3 |
| Feb 5, 2025 | 6593.4 | -52.1 | -0.78% | 6645.5 | 6692.2 | 6577.4 |
| Feb 4, 2025 | 6644.3 | -166.6 | -2.45% | 6810.9 | 6835.2 | 6581.4 |
| Feb 3, 2025 | 6687.4 | 156.7 | 2.40% | 6530.7 | 6813.4 | 6530.5 |
| Jan 31, 2025 | 6759.3 | 262.6 | 4.04% | 6496.7 | 6795.2 | 6490.5 |
| Jan 30, 2025 | 6347.8 | -70.8 | -1.10% | 6418.6 | 6462.6 | 6281.9 |
| Jan 29, 2025 | 6380.7 | 2.9 | 0.05% | 6377.8 | 6464.0 | 6343.8 |
| Jan 28, 2025 | 6400.5 | -55.4 | -0.86% | 6455.9 | 6474.1 | 6367.8 |
| Jan 27, 2025 | 6460.7 | -84.8 | -1.30% | 6545.5 | 6591.4 | 6451.5 |
| Jan 24, 2025 | 6490.5 | -83.2 | -1.27% | 6573.7 | 6597.4 | 6433.5 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Chugai Pharmaceutical Co., Ltd. Company profile
About Chugai Pharmaceutical Co Ltd
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chugai Pharmaceutical Co Ltd revenues increased 27% to Y999.76B. Net income increased 41% to Y303B. Revenues reflect Net Sales increase of 27% to Y802.84B, Royalties and other operating revenues increase of 28% to Y196.92B. Dividend per share increased from Y55.00 to Y76.00. Basic Earnings per Share excluding Extraordinary Items increased from Y130.66 to Y184.29.
Equity composition
FY'03, the Co. changed FY end from March to December. FY'94-'02 WAS & FY'04 Q1 &Q3 WAs & O/S were estimated. 3/05 & 9/05, WAS, O/S, DPS were estimated. FY'06 Q3 & '07 Q1, Q3 WAS& DWAS were estimated, and its WAS was used as O/S. FY'08 1Q WAS & DWAS were estimated and WAS was used as o/s. FY'08 Q3 WAS estimated and used as o/s.
| Industry: | Pharmaceuticals (NEC) |
日本橋三井タワー15f
日本橋室町2-1-1
CHUO-KU
TOKYO-TO 103-8324
JP
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com